用于炎症性肠病临床试验和临床实践的患者报告结局测量工具:一项系统综述
该研究系统检索多个数据库,最终纳入17篇文章、20种用于评估炎症性肠病(IBD)疾病活动的患者报告结局测量工具(PROM),按美国食品药品监督管理局(FDA)推荐标准评估其测量学性能。结果显示,没有任何一种PROM满足FDA推荐的全部标准;仅6种PROM以内镜检查结果为参照标准验证为IBD活动性标志物,曲线下面积为0.63-0.82;其中用于克罗恩病和溃疡性结肠炎的移动健康指数(mobile health index)评分在临床实践和临床试验中的测量学性能最佳。
要点
- 20种用于评估IBD活动的PROM中,没有任何一种满足FDA推荐的全部标准。
- 仅6种PROM以内镜检查结果为参照标准验证为IBD活动性标志物,曲线下面积为0.63-0.82。
- 移动健康指数(克罗恩病和溃疡性结肠炎)评分在临床实践和临床试验中测量学性能最佳。
核心结论
- 系统综述识别出20余种已开发和测试的、用于评估IBD活动的PROM,但均未满足FDA推荐的全部标准;需进一步研究确定其准确性及其在常规实践、临床试验、远程医疗系统和价值医疗项目中的有效应用。
研究设计与样本
- 系统综述:检索PubMed、Medline、Cochrane图书馆和Embase数据库,初检获973篇文章,由2名独立审阅者筛选,37篇关于PROM开发或验证的文章进入进一步分析,最终纳入17篇文章、20种不同的PROM。
- 依据美国食品药品监督管理局(FDA)的推荐,评估内容效度、结构效度和标准效度、信度以及对变化的反应性,并收集临床实践中易用性的数据。
主要发现
- 仅2种PROM在开发过程中报告了患者参与:患者报告Harvey Bradshaw指数和简易临床结肠炎活动指数(Simple Clinical Colitis Activity Index)评分。
- 仅6种PROM以内镜检查结果为参照标准验证为IBD活动性标志物:患者总体评估、患者疾病活动评估、克罗恩病移动健康指数、溃疡性结肠炎移动健康指数、源自Mayo评分的患者报告结局和6分Mayo评分;这些PROM识别黏膜炎症的曲线下面积为0.63-0.82。
- 克罗恩病和溃疡性结肠炎移动健康指数评分在临床实践和临床试验中的测量学性能最佳。
关键数值与推荐
- 以内镜检查结果为参照标准,6种验证为IBD活动性标志物的PROM识别黏膜炎症的曲线下面积为0.63-0.82。
- 在开发过程中报告患者参与的PROM仅2种:患者报告Harvey Bradshaw指数和简易临床结肠炎活动指数评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mucosal inflammation must be carefully monitored to improve the long-term outcomes of patients with inflammatory bowel diseases (IBD). Patient-reported outcome measures (PROMs) are used increasingly to monitor disease activity in clinical practice and as endpoints in clinical trials. We performed a systematic review to provide an overview of the available PROMs on IBD activity and to evaluate their diagnostic value. METHODS: A systematic search of the PubMed, Medline, Cochrane library, and Embase databases using defined keywords, identified 973 articles. These were screened by 2 independent reviewers, and 37 articles on development or validation of PROMs to assess IBD activity were identified for further analysis. Based on the recommendations of the Food and Drug Administration (FDA), the following measurement properties were evaluated: content, construct, and criterion validity; reliability; and responsiveness to change. In addition, data on ease of use in clinical practice were collected. RESULTS: Seventeen articles presenting 20 different PROMs were included the final analysis, although none met all the FDA-recommended criteria. Only 2 PROMs (patient-reported Harvey Bradshaw Index and Simple Clinical Colitis Activity Index scores) reported patient involvement during its development. Only 6 PROMs (patient-reported global assessment, patient assessment of disease activity, mobile health index for Crohn's disease, mobile health index for ulcerative colitis, patient-reported outcome derived from the Mayo score, and the 6-point Mayo score) were validated as markers of IBD activity, using findings from endoscopy as the reference standard; these PROMs identified patients with mucosal inflammation with area under the curve values of 0.63-0.82. The mobile health index for CD and UC scores had the best measurement properties for use in clinical practice and in clinical trials. CONCLUSIONS: In a systematic review, we identified more than 20 PROMS that have been developed and tested for their ability to determine IBD activity. Further studies are needed to determine their accuracy and whether they can be used effectively in routine practice, clinical trials, telemedicine systems, and value-based healthcare programs.
引用
- de Jong MJ, Huibregtse R, Masclee AAM, et al. Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review. Clin Gastroenterol Hepatol. 2017. PMID: 29074448. doi:10.1016/j.cgh.2017.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。